These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 35197856)

  • 1. Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Zhang MZ; Bao W; Zheng QY; Wang YH; Sun LY
    Front Pharmacol; 2022; 13():819327. PubMed ID: 35197856
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials.
    Bao W; Zhang M; Li N; Yao Z; Sun L
    Eur J Clin Pharmacol; 2022 Dec; 78(12):1877-1887. PubMed ID: 36273065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis.
    Fu Z; Geng X; Chi K; Song C; Wu D; Liu C; Hong Q
    Ann Palliat Med; 2021 Jul; 10(7):7428-7439. PubMed ID: 34353035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-Analysis of the Efficacy and Safety of Finerenone in Diabetic Kidney Disease.
    Zheng Y; Ma S; Huang Q; Fang Y; Tan H; Chen Y; Li C
    Kidney Blood Press Res; 2022; 47(4):219-228. PubMed ID: 35034019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis.
    Jiang X; Zhang Z; Li C; Zhang S; Su Q; Yang S; Liu X; Hu Y; Pu X
    Front Pharmacol; 2022; 13():896947. PubMed ID: 35784710
    [No Abstract]   [Full Text] [Related]  

  • 6. Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis.
    Rosas SE; Ruilope LM; Anker SD; Pitt B; Rossing P; Bonfanti AAC; Correa-Rotter R; González F; Munoz CFJ; Pergola P; Umpierrez GE; Scalise A; Scott C; Lawatscheck R; Joseph A; Bakris GL;
    Kidney Med; 2023 Oct; 5(10):100704. PubMed ID: 37745646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
    Bakris GL; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Kolkhof P; Joseph A; Pieper A; Kimmeskamp-Kirschbaum N; Ruilope LM;
    JAMA; 2015 Sep; 314(9):884-94. PubMed ID: 26325557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Systematic Review and Meta-Analysis on the Efficacy and Safety of Finerenone Therapy in Patients with Cardiovascular and Chronic Kidney Diseases in Type 2 Diabetes Mellitus.
    Jyotsna F; Mahfooz K; Patel T; Parshant F; Simran F; Harsha F; Neha F; Jyotishna D; Mishra D; Subedi S; Khatri M; Kumar S; Varrassi G
    Cureus; 2023 Jul; 15(7):e41746. PubMed ID: 37575756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.
    Pei H; Wang W; Zhao D; Wang L; Su GH; Zhao Z
    Medicine (Baltimore); 2018 Apr; 97(16):e0254. PubMed ID: 29668577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists for renal and cardiovascular outcomes in patients with chronic kidney disease: a meta-analysis of randomized clinical trials.
    Chen Q; Wei G; Wang Y; Li X; Zhao Q; Zhu L; Xiao Q; Xiong X
    Front Pharmacol; 2024; 15():1338044. PubMed ID: 38476327
    [No Abstract]   [Full Text] [Related]  

  • 11. Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials.
    Flack JM; Agarwal R; Anker SD; Pitt B; Ruilope LM; Rossing P; Adler SG; Fried L; Jamerson K; Toto R; Brinker M; Farjat AE; Kolkhof P; Lawatscheck R; Joseph A; Bakris GL;
    Kidney Med; 2023 Dec; 5(12):100730. PubMed ID: 38046911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cardiovascular outcomes of finerenone in patients with chronic kidney disease and type 2 diabetes: A meta-analysis of randomized clinical trials.
    Abdelazeem B; Elbadawy MA; Awad AK; Kheiri B; Kunadi A
    Intractable Rare Dis Res; 2022 Feb; 11(1):31-33. PubMed ID: 35261849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in the Management of Diabetic Kidney Disease: A Meta-analysis.
    Dutta D; Surana V; Bhattacharya S; Aggarwal S; Sharma M
    Indian J Endocrinol Metab; 2022; 26(3):198-205. PubMed ID: 36248038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Finerenone for Prevention of Cardiovascular Events in Type 2 Diabetes Mellitus With Chronic Kidney Disease: A Meta-analysis of Randomized Controlled Trials.
    Yang S; Shen W; Zhang HZ; Wang CX; Yu WQ; Wu QH
    J Cardiovasc Pharmacol; 2023 Jan; 81(1):55-62. PubMed ID: 36027585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials.
    Du Y; Cao G; Gu L; Chen Y; Liu J
    Front Pharmacol; 2023; 14():1237583. PubMed ID: 38273834
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis.
    Yasmin F; Aamir M; Najeeb H; Atif AR; Siddiqui AH; Ahsan MN; Moeed A; Ali SH; Tahir HM; Asghar MS
    Ann Med Surg (Lond); 2023 Oct; 85(10):4973-4980. PubMed ID: 37811017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis.
    Ghosal S; Sinha B
    Front Endocrinol (Lausanne); 2023; 14():1114894. PubMed ID: 36742404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
    Filippatos G; Anker SD; Agarwal R; Pitt B; Ruilope LM; Rossing P; Kolkhof P; Schloemer P; Tornus I; Joseph A; Bakris GL;
    Circulation; 2021 Feb; 143(6):540-552. PubMed ID: 33198491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease.
    Zhang Y; Wang J; Jiang L; Wang T; Li Z; Fu X; Huang W; Xiao Y; Wang S; Zhao J
    Diabetol Metab Syndr; 2022 Oct; 14(1):156. PubMed ID: 36303247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.